Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals ( ($CRVS) ) has shared an update. On June 11, 2026, Corvus Pharmaceuticals held its 2026 Annual Meeting of Stockholders, wit...

Corvus Stockholders Approve Directors and Governance Proposals

In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Corvus Pharmaceuticals, with a price target of $30....

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRVS	$11.74	-1.34%	1.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRVS	$11.74	-1.3%	1.18M
3
4
5
6

CRVS

CRVS

Get Corvus Pharmaceuticals Inc. Data in Excel

Get Corvus Pharmaceuticals Inc. Data in Excel